Loading organizations...
Boulder, Colorado-based ArcherDX develops a molecular pathology platform utilizing next-generation sequencing and proprietary anchored multiplexed polymerase chain reaction technology to detect genetic mutations for precision oncology. Prior to its corporate acquisition, the business generated approximately $50 million in annual revenue during 2019 by selling specialized assay kits and bioinformatics software to clinical diagnostic laboratories and academic research institutions. The enterprise successfully secured over $150 million in venture funding across multiple rounds before being acquired by medical genetics firm Invitae for $1.4 billion in cash and stock in October 2020. Throughout its independent operational history, ArcherDX established strategic research partnerships and customer relationships with major biopharmaceutical and sequencing industry players, including Bristol Myers Squibb, AstraZeneca, and Illumina. The molecular diagnostics company was originally founded in 2013 by Jason Myers, A. John Iafrate, and Long Phi Le.
ArcherDX has raised $150.0M across 3 funding rounds.
ArcherDX has raised $150.0M in total across 3 funding rounds.
ArcherDX has raised $150.0M across 3 funding rounds. Most recently, it raised $55.0M Series C in December 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 17, 2019 | $55M Series C | Michael Altman | ArrowMark Partners, Boulder Ventures, Driehaus Capital Management, Longwood Fund, PBM Capital, Redmile Group, Sands Capital, Soleus Capital | Announced |
| May 15, 2019 | $60M Series B | SAM Chawla | Boulder Ventures, Longwood Fund, PBM Capital, Peierls Foundation | Announced |
| Mar 20, 2018 | $35M Series A | Kyle Lefkoff, PBM Capital | Longwood Fund, Peierls Foundation | Announced |
ArcherDX has raised $150.0M in total across 3 funding rounds.
ArcherDX's investors include Michael Altman, ArrowMark Partners, Boulder Ventures, Driehaus Capital Management, Longwood Fund, PBM Capital, Redmile Group, Sands Capital, Soleus Capital, Sam Chawla, Peierls Foundation, Kyle Lefkoff.
